Christine Pacheco

Christine Pacheco

Auto-generated profile, based on publicly available information

Christine Pacheco

Department of Cardiology, Université de Montréal, Quebec, Canada (C.P.).

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
CNColleen M. Norris
Colleen M. Norris
CYCindy Y. Y. Yip
Cindy Y. Y. Yip
KNKara A. Nerenberg
Kara A. Nerenberg
MCMarie-Annick Clavel
Marie-Annick Clavel
CPChristine Pacheco
Christine Pacheco
SMSharon L. Mulvagh
Sharon L. Mulvagh

27 July 2018
Verified
Book Chapter
Closed access
PDF file
CSChrisandra Shufelt
Chrisandra Shufelt
CPChristine Pacheco
Christine Pacheco
MTMarysia S. Tweet
Marysia S. Tweet
VMVirginia M. Miller
Virginia M. Miller

1 February 2018 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
CCChristine Pacheco Claudio
Christine Pacheco Claudio
OQOdayme Quesada
Odayme Quesada
CPCarl J Pepine
Carl J Pepine
C. Noel Bairey MerzC. Noel Bairey Merz
C. Noel Bairey Merz

22 November 2018 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
MTMaxime Tremblay‐Gravel
Maxime Tremblay‐Gravel
GMGuillaume Marquis‐Gravel
Guillaume Marquis‐Gravel
RARobert Avram
Robert Avram
ODOlivier Desplantie
Olivier Desplantie
ADAnique Ducharme
Anique Ducharme
OIon behalf of the BRO‐HF investigators
on behalf of the BRO‐HF investigators
Aims Bromocriptine is thought to facilitate left ventricular (LV) recovery in peripartum cardiomyopathy (PPCM) through inhibition of prolactin secretion. However, this potential therapeutic effect remains controversial and was incompletely studied in diverse populations. Methods and results Consecutive women with new‐onset PPCM (n = 76) between 1994 and 2015 in Quebec, Canada, were classified according to treatment (n = 8, 11%) vs. no treatment (n = 68, 89%) with bromocriptine. We assessed LV functional recovery at mid‐term (6 months) and long‐term (last follow‐up) and compared outcomes among groups. Women treated with bromocriptine experienced better mid‐term left ventricular ejection fraction (LVEF) recovery from 23 ± 10% at baseline to 55 ± 12% at 6 months, compared with a change from 30 ± 12% at baseline to 45 ± 13% at 6 months in women treated with standard medical therapy (P interaction < 0.01). At long‐term, a similar positive association was found with bromocriptine (9% greater LVEF variation, P interaction < 0.01). In linear regressions adjusted for obstetrical, clinical, echocardiographic, and pharmacological variables, treatment with bromocriptine was associated with a greater improvement in LVEF [β coefficient (standard error), 14.1 (4.4); P = 0.03]. However, there was no significant association between bromocriptine use and the combined occurrence of all‐cause death and heart failure events (hazard ratio, 1.18; 95% confidence interval, 0.15 to 9.31), using univariable Cox regressions based over a cumulative follow‐up period of 285 patient‐years. Conclusions In women newly diagnosed with PPCM, treatment with bromocriptine was independently associated with greater LV functional recovery.

6 December 2022 in Maturitas
Verified
Journal Article
Closed access
TDTara D'IGnazio
Tara D'IGnazio
SGSophie Grand'MAison
Sophie Grand'MAison
LBLyne Bérubé
Lyne Bérubé
JFJessica Forcillo
Jessica Forcillo
CPChristine Pacheco
Christine Pacheco

1 January 2014 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
CLClaudio
Claudio
CCChristine Pacheco Claudio
Christine Pacheco Claudio
ECEmmanuel Charbonney
Emmanuel Charbonney
MDMadeleine Durand
Madeleine Durand
CKChristophe Kolan
Christophe Kolan
MLMikhael Laskine
Mikhael Laskine
Diffuse alveolar hemorrhage (DAH) is a rare and potentially deadly complication of systemic lupus erythematosus (SLE). We report two adult cases where extracorporeal membrane oxygenation (ECMO) was used as rescue therapy for severe respiratory failure in this setting. We discuss the risk related to coagulation disturbance and the need for the circuit anticoagulation in this particular setting. We also briefly discuss the clinical problem of lack of knowledge on the bioavailability of the immunosuppressive treatment with the use of ECMO. We think that ECMO should be used as rescue therapy in patients with DAH caused by SLE, but strategies for anticoagulation require further precision.J Clin Med Res. 2014;6(2):145-148doi: http://dx.doi.org/10.14740/jocmr1685w